Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 14 recruiting now full pipeline

Eosinophilic Esophagitis: full-pipeline trial registry

14 of 45 indexed Eosinophilic Esophagitis trials are currently recruiting.

Corpus placement: #323 of 28,707 conditions by registered trial count.

45 US clinical trials · 14 currently recruiting · #323 of 28,707 conditions by registered trial count

Eosinophilic Esophagitis: 45 US clinical trials tracked, 14 recruiting.

Eosinophilic Esophagitis is the subject of 45 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is Ann & Robert H Lurie Children's Hospital of Chicago, running 6 of these trials.

Enrollment posture brief

Registry condition eosinophilic-esophagitis

OPEN 14 | RECR 31% | LATE 8 | EARLY 12 | RANK #323 | SPON 6

Nearest open-share peer: Chronic Kidney Disease (31% recruiting · 103 trials)

Asthma in Children66.7%Cannabis Use64.4%Cognitive Change55.6%Gastroparesis53.3%Eosinophilic Esophagitis (th…31%
Open-enrollment share among volume-matched conditions near Eosinophilic Esophagitis

Eosinophilic Esophagitis lists 14 open slots (31% of 45 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Eosinophilic Esophagitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Eosinophilic Esophagitis is recruiting below its size-band peers.

    14 of 45 indexed trials (31.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Eosinophilic Esophagitis trials is spread across many organizations.

    Ann & Robert H Lurie Children's Hospital of Chicago accounts for 6 of 45 trials (13.3%). 28 distinct sponsors appear on at least one study for this condition label.

  3. Typical Eosinophilic Esophagitis enrolment sits around 80 participants.

    Median target enrolment is 80 among the 45 trials that report a genuine target (sentinel values excluded). 26 of those (57.8%) plan for fewer than 100 participants.

  4. Eosinophilic Esophagitis splits between interventional and observational designs.

    28 interventional and 17 observational studies make up this index (62.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 210Phase 35Phase 43

Open and recent trials

45 total, page 1 of 1

RECRUITING 23,000 participants

A Registry for the Food Allergy Community

Food Allergy Research & Education

NCT04653324

RECRUITING 5,000 participants

Indiana University Gastrointestinal Motility Diagnosis Registry

Indiana University

NCT04506593

RECRUITING 1,800 participants

Natural History and Genetics of Food Allergy and Related Conditions

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02504853

RECRUITING 1,500 participants

Characteristics and Inflammatory Markers in Children with Eosinophilic Esophagitis (EoE)

University of California, San Diego

NCT03980886

RECRUITING 1,350 participants

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

Children's Hospital Medical Center, Cincinnati

NCT02523118

RECRUITING 500 participants

Eosinophilic Gastrointestinal Disorders Registry

Ann & Robert H Lurie Children's Hospital of Chicago

NCT05199532

RECRUITING Phase 3 308 participants

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

Dr. Falk Pharma

NCT06596252

RECRUITING Phase 2 80 participants

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

Phathom Pharmaceuticals

NCT06851559

RECRUITING Phase 2 72 participants

Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE

University of Colorado, Denver

NCT06705387

RECRUITING NA 70 participants

The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07027826

RECRUITING 50 participants

Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:

Medical College of Wisconsin

NCT07227506

RECRUITING NA 40 participants

Patient-Centered Decision Support for Eosinophilic Esophagitis

University of Michigan

NCT06817213

RECRUITING Phase 2 15 participants

Zemaira Eosinophilic Esophagitis Pilot Study

Children's Hospital Medical Center, Cincinnati

NCT05485155

RECRUITING 10 participants

Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study

Indiana University

NCT03312686

ACTIVE NOT RECRUITING 800 participants

Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

University of North Carolina, Chapel Hill

NCT01988285

ACTIVE NOT RECRUITING 440 participants

Esophageal String Test in Eosinophilic Esophagitis

University of Colorado, Denver

NCT02008903

ACTIVE NOT RECRUITING Phase 3 368 participants

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

AstraZeneca

NCT05583227

ACTIVE NOT RECRUITING Phase 3 368 participants

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Celgene

NCT04991935

ACTIVE NOT RECRUITING 300 participants

Prospective Database for Eosinophilic Esophagitis (EoE) of Pediatric Population

Ann & Robert H Lurie Children's Hospital of Chicago

NCT05176249

ACTIVE NOT RECRUITING NA 100 participants

The Immune Directed Individualized Elimination Therapy (iDIET) Study

University of North Carolina, Chapel Hill

NCT05543512

ACTIVE NOT RECRUITING NA 96 participants

Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus

Massachusetts General Hospital

NCT02202590

ACTIVE NOT RECRUITING Phase 4 90 participants

Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)

University of Colorado, Denver

NCT04149470

ACTIVE NOT RECRUITING 88 participants

Inflammatory Mediators as Potential Non-Invasive Biomarkers in Subjects With Eosinophilic Esophagitis

Ann & Robert H Lurie Children's Hospital of Chicago

NCT03822325

ACTIVE NOT RECRUITING 64 participants

A Prospective Study of the Four Food Elimination Diet for Treatment of Eosinophilic Esophagitis

Ann & Robert H Lurie Children's Hospital of Chicago

NCT05176262

ACTIVE NOT RECRUITING 54 participants

Morphological Markers of Gastroesophageal Reflux Disease (GERD)

Baylor College of Medicine

NCT01921686

ACTIVE NOT RECRUITING 54 participants

Cow's Milk Elimination for Treatment of Eosinophilic Esophagitis

Ann & Robert H Lurie Children's Hospital of Chicago

NCT05083156

ACTIVE NOT RECRUITING 50 participants

Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children

Ann & Robert H Lurie Children's Hospital of Chicago

NCT05309590

COMPLETED Phase 3 321 participants

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

Regeneron Pharmaceuticals

NCT03633617

COMPLETED Phase 2 227 participants

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

Ception Therapeutics

NCT00538434

COMPLETED NA 179 participants

Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies

Children's Hospital Medical Center, Cincinnati

NCT02038894

COMPLETED Phase 3 143 participants

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

Ellodi Pharmaceuticals

NCT04281108

COMPLETED Phase 2 108 participants

A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis

Pfizer

NCT04682639

COMPLETED Phase 2 100 participants

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

Celgene

NCT02098473

COMPLETED Phase 2 51 participants

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

Mayo Clinic

NCT00728481

COMPLETED Phase 2 42 participants

A Study of Flovent in Patients With Eosinophilic Esophagitis

Marc Rothenberg, MD

NCT00426283

COMPLETED Phase 2 25 participants

Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis

Novartis Pharmaceuticals

NCT01022970

COMPLETED Phase 1 24 participants

Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis

Forest Laboratories

NCT01386112

COMPLETED NA 22 participants

Cytosponge and Dietary Therapy in EoE

Mayo Clinic

NCT02599558

COMPLETED NA 22 participants

A Food Additive Removal Diet for Pediatric Eosinophilic Esophagitis

Nemours Children's Clinic

NCT03657771

COMPLETED Phase 4 21 participants

Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis

Children's Hospital of Philadelphia

NCT05247866

COMPLETED NA 21 participants

Use of Esophageal String Test to Understand Symptoms, Inflammation, and Function in Eosinophilic Esophagitis

University of Colorado, Denver

NCT03305653

COMPLETED Phase 4 16 participants

Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis

University of Tennessee

NCT02371941

COMPLETED 16 participants

a4b7 Integrin in Eosinophilic Esophagitis

Massachusetts General Hospital

NCT02546219

COMPLETED Early Phase 1 8 participants

Radiation Dose in Humans From Orally Administered Tc99m-Heparin

University of Utah

NCT04069429

COMPLETED Phase 2 6 participants

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

Children's Hospital Medical Center, Cincinnati

NCT01808196

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 10
Phase 3 5
Phase 4 3

Named interventions

Most-linked intervention names on Eosinophilic Esophagitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Budesonide Drug
2 trials
Esophagogastroduodenoscopy Procedure
2 trials
Dupilumab Drug
2 trials
Placebo Other
2 trials
Zofran - no intubation Drug
1 trials
Intubated with Propofol (IP) Drug
1 trials
Intubated with Sevoflurane (IS) Drug
1 trials

US sites by state

Facility locations filed on Eosinophilic Esophagitis trials. A trial with sites in several states counts in each.

Illinois 15 trials
Colorado 13 trials
California 11 trials
Arizona 9 trials
Arkansas 9 trials
Ohio 8 trials
Minnesota 8 trials
Maryland 8 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Eosinophilic Esophagitis page

45 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Eosinophilic Esophagitis condition card totals 45 registered trials; most-linked intervention Placebo; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.